This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, … expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner … partnership is another validation of our leadership in ADAR-mediated RNA editing, our robust IP estate, and the …
… with the idea to hijack the endogenous RNA editing enzyme ‘ADAR’ in our cells and to redirect it to any target of … oligonucleotides that will go in to a cell and attract the ADAR enzymes to a particular site on the RNA that they want …
